Chastened Innate Returns Lumoxiti Rights To AZ
Struggled To Commercialize Hairy Cell Leukemia Drug
The French firm gave back the rights to Lumoxiti on the same day the drug got a thumbs up from the CHMP after struggling to market the rare leukemia drug in the US.
You may also be interested in...
AstraZeneca Pulls Plug On Lumoxiti Due To Low Uptake
Signs of trouble were already emerging in 2020 when Innate backed out of a co-commercialization pact. AstraZeneca plans to discontinue the hairy cell leukemia ADC in July.
AstraZeneca Finds Two More Potential Partners For Imfinzi
Adding oleclumab and monalizumab to the PD-L1 inhibitor improved PFS, while another study showed improved real-world outcomes.
Deal Watch: GSK Makes $85m Wager On Surface’s Preclinical NK Cell Therapy
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.